
Swanbridge Capital
AI Verified
Netherlands
Venture Capital
16 Marconistraat, 3029 AK Rotterdam, South Holland, Netherlands
2016
Criteria | Requirements | Match |
---|---|---|
Regions | Northern Europe, Western Europe |
00
|
Countries |
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
|
00
|
Sector |
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
|
00
|
Impact Area |
00 00 00
|
|
Stage | Seed, Series A, Bridge, Pre-Seed |
00
|
Ticket size |
00 00 00
-
00 00 00
USD
|
00
|
Monetization model |
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
|
00
|
Product readiness |
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
|
00
|
Client types |
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
|
00
|
Min. revenue |
00 00 00
USD
|
00
|
Other |
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
|
- |
Company description
Swanbridge Capital operates as a specialized venture capital fund headquartered in Rotterdam, focusing exclusively on early-stage healthcare innovations. The firm strategically directs its investments toward promising startups developing novel therapeutics, cutting-edge diagnostic technologies, and innovative medical devices that address significant unmet medical needs. With a dedicated team of life science experts and investment professionals, Swanbridge has established itself as a key player in the European biotech investment landscape since its founding.
What distinguishes Swanbridge from many other venture capital entities is its willingness to engage with companies at the pre-proof-of-concept stage, a phase many traditional investors consider too risky. This early involvement allows the fund to support groundbreaking technologies when they most need capital infusion, often before clinical validation or regulatory approval processes have been completed. Their investment thesis centers on identifying scientifically sound innovations with significant commercial potential that could transform patient care pathways.
The fund employs a hands-on investment approach, going well beyond merely providing financial resources. Swanbridge's partners actively participate in strategic decision-making, business development initiatives, and operational improvements within their portfolio companies. This collaborative model includes offering expertise in clinical development strategies, regulatory navigation, intellectual property management, and facilitating connections with potential pharmaceutical partners. Their team typically takes board positions and works closely with founding scientists and management teams to accelerate development timelines and enhance company value.
Swanbridge's portfolio reflects its commitment to advancing healthcare innovation across multiple therapeutic areas, including oncology, neurology, and rare diseases. The fund typically makes initial investments ranging from early seed rounds through Series A financing, with capital reserved for follow-on investments in promising portfolio companies. Their investment strategy emphasizes technologies with clear differentiation, strong intellectual property protection, and addressing substantial market opportunities. For entrepreneurs seeking not just financial backing but also strategic guidance and industry connections, Swanbridge Capital positions itself as a value-added partner throughout the challenging journey from scientific discovery to commercial success.
Highlights
Ready to raise better?
Create your Free Account!
Frequently asked questions
Swanbridge Capital maintains its global headquarters in Netherlands, serving as the strategic center for its operations. The company's primary corporate offices are located at 16 Marconistraat, 3029 AK Rotterdam, South Holland, Netherlands.
Swanbridge Capital focuses its investment activities on companies operating in the following stages: Seed, Series A, Bridge, Pre-Seed. Swanbridge Capital provides strategic capital and expertise to support promising businesses at these critical phases of development.
Swanbridge Capital maintains a strategic global investment presence, actively seeking opportunities across the following key regions: Northern Europe, Western Europe.
Swanbridge Capital was established in 2016, marking the beginning of its journey as an investment firm.
Swanbridge Capital is the following type of investment firm: Venture Capital. The organization provides capital and strategic support to entrepreneurs and growing companies.